Vivesto Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
VIVE
- Investments
-
2
- Share Price
-
$0.71
- (As of Monday Closing)
Vivesto General Information
Description
Vivesto AB is a Swedish drug development company developing treatment options for difficult-to-treat cancers with high medical need and market potential. The company focuses on hematological cancers, particularly acute myeloid leukemia (AML). Its project portfolio consists of Cantrixil, which is being evaluated in the preclinical phase for refractory human AML, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a clinical pilot study in dogs with splenic hemangiosarcoma (HSA) following splenectomy and in a dose-finding study in cats with solid tumors.
Contact Information
Website
www.vivesto.comCorporate Office
- Gustav III:s Boulevard 46
- 5th floor
- 169 73 Solna
- Sweden
Corporate Office
- Gustav III:s Boulevard 46
- 5th floor
- 169 73 Solna
- Sweden
Vivesto Stock Performance
As of 16-Nov-2026, Vivesto’s stock price is $0.71. Its current market cap is $7.87M with 11.1M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.71 | $0.72 | $0.65 - $2.20 | $7.87M | 11.1M | 8.19K | -$0.44 |
Vivesto Financials Summary
As of 30-Jun-2026, Vivesto has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,445 | 7,748 | 10,462 | 14,158 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,281) | (3,260) | (3,457) | (11,647) |
| Net Income | (3,369) | (3,469) | (3,759) | (12,112) |
| Total Assets | 17,347 | 16,197 | 15,669 | 22,081 |
| Total Debt | 0 | 1,413 | 134 | 0 |
Vivesto Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vivesto Patents
Vivesto Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026130838-A1 | The combination of trx-e-002-1 with a bcl-2 inhibitor or a hypomethylating agent in the treatment of acute myeloid leukemia | Pending | 17-Dec-2024 | ||
| WO-2026013253-A1 | Process for the preparation of n-retinoyl-l-cysteic acid methyl esters | Pending | 11-Jul-2024 | ||
| AU-2023353939-A1 | Solubilizing compounds | Pending | 26-Sep-2022 | ||
| EP-4593959-A1 | Solubilizing compounds | Pending | 26-Sep-2022 | ||
| US-20260337156-A1 | Solubilizing compounds | Pending | 26-Sep-2022 | C07C309/51 |
Vivesto Signals
Vivesto Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vivesto Investments (2)
Vivesto’s most recent deal was a Corporate Asset Purchase with Kazia Therapeutics (Cantrixil) for . The deal was made on 29-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kazia Therapeutics (Cantrixil) | 29-Mar-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Karo Pharma (Cancer Project KB9520) | 24-Oct-2016 | Corporate Asset Purchase | Buildings and Property |
Vivesto ESG
Risk Overview
Risk Rating
Updated October, 31, 2023
25.61 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Vivesto FAQs
-
When was Vivesto founded?
Vivesto was founded in 1999.
-
Where is Vivesto headquartered?
Vivesto is headquartered in Solna, Sweden.
-
What is the size of Vivesto?
Vivesto has 5 total employees.
-
What industry is Vivesto in?
Vivesto’s primary industry is Drug Discovery.
-
Is Vivesto a private or public company?
Vivesto is a Public company.
-
What is Vivesto’s stock symbol?
The ticker symbol for Vivesto is VIVE.
-
What is the current stock price of Vivesto?
As of 16-Nov-2026 the stock price of Vivesto is $0.71.
-
What is the current market cap of Vivesto?
The current market capitalization of Vivesto is $7.87M.
-
What is Vivesto’s annual earnings per share (EPS)?
Vivesto’s EPS for 12 months was -$0.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process